These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 25591547)

  • 21. Predictors of Drug Shortages and Association with Generic Drug Prices: A Retrospective Cohort Study.
    Dave CV; Pawar A; Fox ER; Brill G; Kesselheim AS
    Value Health; 2018 Nov; 21(11):1286-1290. PubMed ID: 30442275
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmaceutical pricing, price controls, and their effects on pharmaceutical sales and research and development expenditures in the European Union.
    Vogel RJ
    Clin Ther; 2004 Aug; 26(8):1327-40; discussion 1326. PubMed ID: 15476914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Challenges to sovereign ambitions: forces of convergence and divergence within the global pharmaceutical sector and the UK's withdrawal from the European Union.
    Wright JSF; Doukas D
    Health Econ Policy Law; 2021 Jul; 16(3):256-272. PubMed ID: 32583755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Impact Reimbursement Act on the pharmaceutical market in Poland].
    Giermaziak W
    Pol Merkur Lekarski; 2014 Apr; 36(214):270-3. PubMed ID: 24868902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Policy making on data exclusivity in the European Union: from industrial interests to legal realities.
    Adamini S; Maarse H; Versluis E; Light DW
    J Health Polit Policy Law; 2009 Dec; 34(6):979-1010. PubMed ID: 20018988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Legal and policy foundations for global generic competition: Promoting affordable drug pricing in developing societies.
    Zapatero Miguel P
    Glob Public Health; 2015; 10(8):901-16. PubMed ID: 25737069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic and technological drivers of generic sterile injectable drug shortages.
    Woodcock J; Wosinska M
    Clin Pharmacol Ther; 2013 Feb; 93(2):170-6. PubMed ID: 23337525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does reimportation reduce price differences for prescription drugs? Lessons from the European Union.
    Kyle MK; Allsbrook JS; Schulman KA
    Health Serv Res; 2008 Aug; 43(4):1308-24. PubMed ID: 18355258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Financial effects of pharmaceutical price regulation on R&D spending by EU versus US firms.
    Golec J; Vernon JA
    Pharmacoeconomics; 2010; 28(8):615-28. PubMed ID: 20617857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmaceutical Regulatory Framework in Ethiopia: A Critical Evaluation of Its Legal Basis and Implementation.
    Suleman S; Woliyi A; Woldemichael K; Tushune K; Duchateau L; Degroote A; Vancauwenberghe R; Bracke N; De Spiegeleer B
    Ethiop J Health Sci; 2016 May; 26(3):259-76. PubMed ID: 27358547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What Is Possible and What Is Not? The Development of a Legal Framework for Drug Pricing Mechanisms in the EU.
    Ernst G
    Eur J Health Law; 2019 Apr; 26(2):120-140. PubMed ID: 31059472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria.
    Vassileva M; Kamusheva M; Manova M; Savova A; Tachkov K; Petrova G
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):733-742. PubMed ID: 30900482
    [No Abstract]   [Full Text] [Related]  

  • 33. Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues.
    Danzon PM
    Pharmacoeconomics; 2018 Dec; 36(12):1395-1405. PubMed ID: 30062518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outstanding regulatory aspects in the European pharmaceutical market.
    Kanavos P; Mossialos E
    Pharmacoeconomics; 1999 Jun; 15(6):519-33. PubMed ID: 10538326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Impact of Price-cap Regulations on Exit by Generic Pharmaceutical Firms.
    Zhang W; Guh D; Sun H; Marra CA; Lynd LD; Anis AH
    Med Care; 2016 Sep; 54(9):884-90. PubMed ID: 27213540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of the legal regime of intellectual property protection in the pharmaceutical market.
    Pashkov VM; Golovanova IA; Olefir AA
    Wiad Lek; 2016; 69(3 pt 2):582-586. PubMed ID: 27717949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The high price of "free" trade: U.S. trade agreements and access to medicines.
    Lopert R; Gleeson D
    J Law Med Ethics; 2013; 41(1):199-223. PubMed ID: 23581666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is parallel trade in medicines compatible with the single European market?
    Senior I
    Pharmacoeconomics; 1992; 1(Suppl 1):70-6. PubMed ID: 10172047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The UK House of Commons report on the influence of the pharmaceutical industry: lessons for equitable access to medicines in Australia.
    Faunce TS; Tomossy GF
    Monash Bioeth Rev; 2005 Apr; 24(2):38-42. PubMed ID: 16208881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The regulatory framework for complementary and alternative medicines in Europe].
    Knöss W; Stolte F; Reh K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):771-8. PubMed ID: 18584103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.